Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Colorectal Cancer Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GPA33 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GPA33 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View GPA33 Products |
| Gene Delivery | GPA33 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View GPA33 Products |
| Benchmark Ab | Anti-GPA33 (Sequence of huA33 / MGD007) Recombinant positive control. |
View GPA33 Products |
| Validator | GPA33 siRNA Set For knockdown verification. |
View GPA33 Products |
| Related Target A | CD3E Synergistic target for Bispecific T-cell Engagers (e.g., DARTs) |
View CD3E Products |
| Related Target B | CEACAM5 Alternative / Combination target in Gastrointestinal Cancers |
View CEACAM5 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human/Mouse/Cyno ortholog proteins available with >95% purity, HEK293 Expressed (Native Glycosylation). |
| Bispecific Heterodimer Validation | High-purity GPA33 and CD3E recombinant proteins for dual-binding SPR/BLI assays. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration. |
| False Positives | Validated siRNA included for specificity checks in cell-based assays. |
Live GPA33 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GPA33 therapeutics is intensifying, with major players shifting focus from traditional mAbs to Bispecific T-cell Engagers (BiTEs/DARTs) and ADCs. As first-generation therapies reach the clinic, the next wave of R&D is targeting optimal affinity tuning to minimize gastrointestinal toxicity while maximizing tumor cell killing in colorectal cancer (CRC).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Bispecific (DART) | MacroGenics (MGD007) | Colorectal Cancer | Heterodimer Validation (Need High-Purity GPA33 & CD3) |
| ADC | Various Innovators | Gastrointestinal Tumors | Internalization Assay (Need HEK293 Expressed ECD-Fc) |
| Radioligand / mAb | Ludwig Institute (huA33) | Advanced CRC | Binding Specificity (Need Sequence Verified Proteins) |